Lichen China Ltd. engages in providing financial and taxation solutions. It also offers educational support, and software and maintenance services. The company was founded by Li Ya on April 13, 2016 and is headquartered in Jinjiang, China.

Iris Energy Ltd. engages in operating institutional grade data centers powered by renewable energy. It operates through the Australia and North America geographical segments. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

Foremost Lithium Resource & Technology Ltd. is a hard rock lithium exploration company which mainly engages in the exploration, acquisition, and development of mineral resources. The company operates through the Canada and United States geographical segments. It holds interest in Manitoba lithium exploration projects: Lac Simard South, Zoro Lithium, Jean Lake Lithium-Gold, Grass River Lithium, Peg North Lithium, Jol Lithium, and Winston Gold & Silver. It four flagship Lithium Lane Projects as well as its Lac Simard South project are located at the tip of the NAFTA superhighway to capitalize on the world's growing EV appetite. The company was founded on July 7, 2005 and is headquartered in Vancouver, Canada.

SINTX Technologies, Inc. engages in the development and commercialization of silicon nitride for medical and non-medical applications. It markets spinal fusion products and develops products for use in total hip and knee joint replacements. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in 1996 and is headquartered in Salt Lake City, UT.

Digital Health Acquisition Corp. operates as a blank check company. It was formed for the purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more businesses. The company was founded on March 30, 2021 and is headquartered Boca Raton, FL.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

Buzzfeed, Inc. is an independent digital media company, which engages in engagement, distribution, and leveraging data. Its cross-platform network includes BuzzFeed Originals, which creates articles, lists, quizzes, and videos, BuzzFeed Media Brands, which consists of a portfolio of identity-driven lifestyle brands including Nifty, Goodful, As/Is, and Tasty, a social food network, BuzzFeed Studios, which produces original content across broadcast, cable, SVOD, film and digital platforms, and BuzzFeed News and HuffPost, which include reporting and investigative journalism, and BuzzFeed Commerce, which develops products and experiences, as well as licensing and other strategic partnerships. The company was founded by Jonah Peretti and John Johnson in November 2006 and is headquartered in New York, NY.

HUYA, Inc. is a holding company, which engages in the development of game live streaming platforms. The company was founded in 2014 and is headquartered in Guangzhou, China.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm's compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.